Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4

US8075903B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Stephen S. Whitehead · Montgomery Village, US
• Brian R. Murphy · Bethesda, US
• Lewis Markoff · Bethesda, US
• Barry Falgout · Rockville, US
• Joseph E. Blaney · Frederick, US
• Kathryn A. Hanley · Las Cruces, US

Key dates

• Filing date: Mar 4, 2009
• Grant date: Dec 13, 2011
• Expiry date: Apr 2, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.